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Background: Mutations in the cyclin-dependent kinase-like 5 gene (CDKL5) located in the Xp22 region have been
shown to cause a subset of atypical Rett syndrome with infantile spasms or early seizures starting in the first
postnatal months.
Methods: We performed mutation screening of CDKL5 in 60 female patients who had been identified as negative
for the methyl CpG-binding protein 2 gene (MECP2) mutations, but who had current or past epilepsy, regardless of
the age of onset, type, and severity. All the exons in the CDKL5 gene and their neighbouring sequences were
examined, and CDKL5 rearrangements were studied by multiplex ligation-dependent probe amplification (MLPA).
Results: Six previously unidentified DNA changes were detected, two of which were disease-causing mutations in
the catalytic domain: a frameshift mutation (c.509_510insGT; p.Glu170GlyfsX36) and a complete deletion of exon 10.
Both were found in patients with seizures that started in the first month of life.
Conclusions: This study demonstrated the importance of CDKL5 mutations as etiological factors in
neurodevelopmental disorders, and indicated that a thorough analysis of the CDKL5 gene sequence and its
rearrangements should be considered in females with Rett syndrome-like phenotypes, severe encephalopathy and
epilepsy with onset before 5 months of age. This study also confirmed the usefulness of MLPA as a diagnostic
screening method for use in clinical practice.
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Rett Syndrome (RTT) is a neurodevelopmental disorder
characterized by loss of spoken language and hand use,
hand stereotypes, and mental retardation [1], and is the
second most common genetic cause of severe mental re-
tardation in females [2]. Although mutations in the me-
thyl CpG-binding protein 2 gene (MECP2) can be found
in 95–97% of individuals with classical RTT and in 50–
70% of those with atypical RTT [1], some patients do
not carry mutations in this gene, suggesting the exist-
ence of other genetic causes of RTT [3].* Correspondence: MARIAISABEL.TEJADAMINGUEZ@osakidetza.net
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reproduction in any medium, provided the orThe cyclin-dependent kinase-like 5 gene (CDKL5) is
located in the Xp22 region and has been found to be
associated with atypical RTT with infantile spasms or
early seizures starting in the first postnatal months
(Hanefeld variant) [4,5]. CDKL5 is composed of 20 coding
exons and codes for a protein of 1,030 amino acids [6].
CDKL5 mRNA is highly expressed in the adult human
brain, which is indicative of its importance in neuronal
function and development [3].
The clinical overlap between patients with mutations
in CDKL5 and patients with RTT caused by mutations
in MECP2 reflects the fact that these genes belong to
the same pathway [7,8]. To date, more than 80 cases of
pathogenic CDKL5 mutations have been reported [9],
but it is likely that many more exist [7]. The presentl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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patients with epilepsy and RTT or other RTT-like phe-
notypes to improve the diagnostic criteria for these
patients and to clarify the pathological mechanisms of
CDKL5 mutations.Methods
Patients
Patients were referred to our diagnostic laboratory for
investigation of MECP2 gene status. We performed mu-
tation screening of CDKL5 in 60 females from this group
who were negative for mutations and large rearrange-
ments in MECP2, and who had current or previous epi-
lepsy, regardless of the age of onset, type, or severity.
Among these, eight patients were clinically diagnosed
with classic RTT, and one with atypical RTT. Twenty
patients were thought to be Angelman-syndrome but they
were negative for mutations and deletions in UBE3A, and
six presented with autistic features. The spectrum of phe-
notypes of the remaining patients was heterogeneous but
with Rett-like features.
These patients were referred by various paediatric neu-
rologists and clinical geneticists throughout Spain, and
were included in the present study after signed informed
consent forms were obtained from the patients’ parents.
One hundred DNA samples from anonymous healthy
female individuals were used as normal controls for
exons 1, 12, 17 and 21 (200 X chromosomes). The sam-
ples were obtained from the Basque Centre for Transfu-
sions and Human Tissues. The samples and associated
data were processed and released by the Basque Biobank
for Research-OEHUN (www.biobanco.org) following
standard operating procedures with appropriate ethical







Location Nucleotide change Am
ch
60 p 1 p Exon 8 c.509_510insGT p.
60 p 1 p Exon 10 c.745-?_825 + ?del —
160 (60p+ 100c) 1 p Exon 12 c.1455_1460delGGCCAA p.
160 (60p+ 100c) 7 (1p+ 6 c) Exon 17 c.2389 G>A p.
160 (60p+ 100c) 6 (1p+ 5 c) Before exon 1 c.-426 C >G —
60 p 1 p Intron 6 c.403+ 27A>G —
160 (60p+ 100c) 2 (1p+ 1c) Exon 21 c.2995 G>A p.
160 (60p+ 100c) 6 (2p+ 4c) Before exon 1 c.-391 G> T —
60 p 2 p Exon 4, 21 c.145+ 17A>G;




*p: Female patients; c: control healthy females.
** New mutations/variants have not been described in any of the 10 Genome databorigins to the patients. The whole project was approved
by the Ethics Committee of Cruces University Hospital.Screening for CDKL5 mutations
CDKL5 coding sequences and each intron/exon bound-
ary were amplified by polymerase chain reaction (PCR),
using previously described primers [10-12], with slight
modifications of the amplification conditions. The PCR
products were analysed using conformation-sensitive gel
electrophoresis (CSGE), after silver-staining following
our protocols [13]. Sequence analysis of genomic frag-
ments with CSGE mobility shifts was carried out on an
ABI PRISM 3130xl automated DNA sequencer (Applied
Biosystems). Exons 4 and 6 were sequenced directly.Rearrangements studies
Genomic rearrangements were examined using multiplex
ligation-dependent probe amplification (MLPA) kits
(P189-A2 and P189-B1, MRC Holland, The Netherlands),
according to the manufacturer’s protocols.RNA isolation and reverse-transcriptase PCR
We used cDNA to study mutations/variations in exons 8
and 12. Total RNA isolation and cDNA synthesis were
performed as described previously [13]. The region from
exon 8 to exon 12 of CDKL5 was amplified by PCR
using the following flanking primers: forward, 5′-CAGA
GTACGTTGCCACCAGA-3′ in exon 8; and reverse, 5′-
GCAGGCCTACACTCAGGTTC-3′ in exon 12. The pri-
mers used to amplify only exon 12 were: forward, 5′-
TGCACACCAAAACCTACCAAGC-3′ at the start of exon
12; and reverse, 5′-GAATGGCTACTGTCCATGTGC-3′
at the end of exon 12.inoacid
ange
Domain Effect Reference**
Glu170GlyfsX36 Catalytic Pathogenic NEW, this study
——————— Catalytic Pathogenic NEW, this study
Ala486_Lys487del C-Ter Unknown Variation NEW, this study
Asp797Asn C-Ter Polymorphism NEW, this study
——————— ———— Polymorphism NEW, this study





Nectoux et al. [26]
Intusoma et al. [27]





Polymorphism Tao et al. [28]
ases revised [15-24].
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on both strands using a BigDye Terminator Kit (Applied
Biosystems) in a 3130xl automated sequencer (Applied
Biosystems).X chromosome inactivation
X-chromosome inactivation was studied by examination
of the highly polymorphic small tandem repeat within
the human androgen receptor gene, using previously
described protocols [14].Results
The pathogenic mutations, variants, and polymorphisms
identified in the current study are listed in Table 1. Six of
them represent DNA changes not previously described in
any of the 10 databases consulted [15-24]. Two of these
new changes were pathogenic, disease-causing mutations
found in two patients with early-onset epileptic seizures
within the first month of life, and were both de novo
mutations not present in their parents.
The first of these two new mutations was a pathogenic
frameshift mutation in exon 8 (c.509_510insGT; p.
Glu170GlyfsX36) producing a truncating protein in the
catalytic domain that contains only 206 amino-acids on
the 1,030 that has CDKL5 protein. The patient was the
first child of healthy parents. She was born in a private
clinic, and we were unable to obtain all the details
related to the delivery, but established that resuscitation
had not been required and the infant’s birth weight was
3,450 g. The infant started to have seizures at 4 weeks of
life, with facial flushing, vomiting and crying. The family
contacted us when the patient was 11 years old with a
clinical diagnosis of RTT, with severe mental and psy-
chomotor retardation, poor social contact, axial hypo-
tonia, spastic tetraparesis and epilepsy refractory to
numerous treatments.
The second new mutation was a complete deletion of
exon 10 (p.745-?_825+ ?del) detected by MLPA (Figure 1A)
and confirmed by cDNA analysis (Figure 1B). Although this
was an in-frame deletion, we considered it likely to be
pathogenic for several reasons: 1) it was a de novo muta-
tion; 2) all exon deletions from exons 1 to 15 in the gen-
omic databases consulted [16,17,19-21] were pathogenic; 3)
it was located within the catalytic domain; and 4) the clin-
ical description of the patient was consistent with that of
others with CDKL5 deletions. This patient was referred to
the Clinical Genetics Unit at 4 years old because of delayed
psychomotor development, gait abnormalities, growth re-
tardation and severe mental retardation. She was the first
child of healthy parents, born by normal delivery after an
uncomplicated pregnancy. She had her first epileptic sei-
zures at 4 weeks old (2–3 times a day) and these seizures
were refractory to treatment. Follow-up until the mostrecent visit, at age 6 years, indicated severe and progressive
deterioration of her psychomotor development.
Four other new DNA variants were identified, includ-
ing c.1455_1460delGGCCAA (loss of lysine and alanine
amino acids) in exon 12. This patient was referred to us
at 3 years 2 months old by a paediatric neurologist be-
cause of developmental delay, absence of speech, sei-
zures, and difficulty in walking (possible ataxia), though
her initial psychomotor development was normal. She
was the second child of healthy parents, and had a
healthy 13-year-old sister. She had her first febrile seiz-
ure at the age of 11 months, and her mother reported
that her development “stopped” after this episode, in-
cluding with respect to her speech (possible regression).
We initially classified this DNA variant as non-
pathogenic because her asymptomatic mother had the
same variant, and both the mother and infant showed
the same cDNA and random X chromosome inactiva-
tion. However, this variant was not present in the 10
genomic databases consulted, or in the 100 normal con-
trol samples, and we therefore reclassified it as an un-
known variation.
The second DNA variant was c.2389 G>A (p. Asp797Asn)
in exon 17. This was inherited from the father and was
therefore not a pathogenic mutation. Six other females in
the healthy control group also showed this change, indi-
cating that it represents a newly-described polymorphism
in Spain.
The remaining two novel DNA changes had no clinical
significance: c.−426 C>G and c.403 + 27A>G. The first
was also found in five healthy female controls, and thus
represented another novel polymorphism for Spain. In
silico studies of the second change using the ESE Finder
program [25] indicated that it was non-pathogenic. Fur-
thermore, a similar change (c.403 + 80 G>A) in the
1,000 genomes database [24] was classified as a single
nucleotide polymorphism (SNP) variant. No parental
DNA was available for either of these cases.
Finally, we detected three previously reported variants.
The variant c.2995 G>A (p.Val999Met), first described by
Nectoux et al.. [26] as likely non-pathogenic and later clas-
sified as a polymorphism [27] and SNP (rs35693326 [18]),
was found in a patient whose asymptomatic mother also
had this variant. This variant was also identified among the
control group, and we therefore concluded that it repre-
sented a gene polymorphism. c.−391 G>T first reported by
Evans et al..[12] was found in two patients and four con-
trols. Finally, the haplotype c.145+17A>G; c. 3003 C>G
and c. 3084 G>A, first described by Tao J et al.. [28], was
found in another two patients.
Discussion
Kalscheuer et al.. [11] in 2003 provided the first report
of mutations in the CDKL5 gene in two unrelated
Figure 1 Complete deletion of exon 10 detected by MLPA (A) and confirmed by cDNA analysis (B).
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due to two different balanced X-autosome transloca-
tions; since then, more than 80 patients with pathogenic
mutations in this gene have been described [29]. The
current study analysed CDKL5 mutations in 60 female
patients with epilepsy, initially thought to be associated
with MECP2 mutations, but who were negative for
mutations and large rearrangements in this gene.
This complete genetic study of CDKL5 (sequencing of
all the exons and their neighbouring sequences and
analysis of gene rearrangements by MLPA) identified
two new, previously undescribed pathogenic mutations,
consisting of one frameshift mutation and one deletion
(2/60, 3%). This rate is lower than those reported by
some other authors (7,6–8%) [7,8,30], but these previous
studies only included patients with precocious epilepsy,
while the current study included patients undergoing
MECP2 screening, but with any type of epilepsy regard-
less of the age of onset.
The two new mutations were found in girls with se-
vere encephalopathy, autistic characteristics, severedeterioration of psychomotor development and onset of
seizures within the first month of life, although there
were some phenotypic differences between the two
cases. These characteristics are in agreement with Bahi-
Buisson et al. [31] and other authors [6,32], who linked
mutations in the CDKL5 gene with various and overlap-
ping phenotypes, ranging from autism and mental re-
tardation to RTT with epilepsy phenotypes.
Recent studies have focused on better characterising
the relationships between genotypes and phenotypes,
given that phenotypic heterogeneity caused by mutations
in CDKL5 is attributable to the nature of the mutations
and their location, to inactivation of the X chromosome,
and to cellular differences caused by these various muta-
tions [31]. Some authors have failed to find any clear re-
lationship between the type of mutation and the severity
of the phenotype [31], but the most recent studies sug-
gest that mutations in the catalytic domain of the pro-
tein (from exon 2 to exon 12; the pathogenic mutations
in the present study were identified in exons 8 and 10)
cause more severe clinical characteristics [7,26,32].
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epileptic seizures within the first 6 months of life distin-
guished patients with CDKL5 mutations from patients
with typical RTT caused by MECP2 mutations, which is
in accordance with the results of the current study.
There is evidence that CDKL5 interacts with MeCP2
and modifies its phosphorylation. Castrén et al. [33] sug-
gested that MECP2 expression levels regulate the
methylation-dependent binding of CDKL5 to MeCP2
and that this interaction may explain the finding that
CDKL5 mutations produce a phenotype with some fea-
tures that overlap with RTT. Other authors [31,34] have
speculated that the variable clinical presentations of
CDKL5-related encephalopathy result from the tran-
scriptional or translational effects of CDKL5 mutations.
Further studies are required to clarify the physiological
interactions between these genes.
X-chromosome inactivation is known to impact on the
clinical manifestations of X-linked disorders; however,
this point cannot be investigated in studies that use
blood, rather than brain cells [8,31], where preferential
inactivation of the mutated chromosome is believed to
occur [33]. Specifically, patients with pathological muta-
tions in the current study had normal, random inactiva-
tion of the X chromosome (58:42 and 56:44).
Finally, this study highlights the importance of analysing
rearrangements of the CDKL5 gene; according to Mei
et al. [35], more than 10% of the mutations in the CDKL5
gene are rearrangements. Two new pathogenic mutations
were identified in the present cohort, one of which was
due to a deletion detected using MLPA (50%).
Conclusions
The results of this study confirm that CDKL5 mutations
are a potentially important etiological factor in neurodeve-
lopmental disorders. Females with RTT-like phenotypes,
severe encephalopathy, and very early-onset epilepsy may
benefit from a complete analysis of the CDKL5 gene, in
terms of both its sequence and its rearrangements. Early
onset was considered to be onset before the age of
5 months [1,36], which was the most consistent clinical
sign associated with CDKL5 mutations. In addition, the
results demonstrate the usefulness of MLPA as a clinical
screening method to establish a causative diagnosis in
these patients. Overall, this study provides an important
contribution to improving the understanding of the
CDKL5 gene and its pathology.
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